Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 09:05:21 01/07/2024 pm IST Pre-market 11:49:08 am
91.85 EUR +2.12% Intraday chart for Sanofi 91.88 +0.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge RE
Market Update-Europe ends the day in the green, relieved after the 1st round of elections in France RE
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June MT
Sanofi could invest up to EUR1.5 bn in its German insulin production site-source RE
Sanofi eyes German insulin investment of up to $1.6 bln, source says RE
Sector Update: Health Care Stocks Mixed Premarket Monday MT
Wall Street Kicks Off H2 as US Equity Futures Waver Pre-Bell MT
'HB': Sanofi plans to invest billions in Frankfurt DP
New semester, new state of mind Our Logo
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion' RE
Sanofi Eyes Up to $1.61 Billion Investment at German Production Site MT
Sanofi Mulls Up to EUR1.5 Billion Investment in Germany MT
Sanofi eyes investment of up to $1.6 billion in Germany, Handelsblatt says RE
CAC40: caution prevails ahead of crucial deadlines CF
CAC40: consolidates solo, OAT/Bund spread widens to 81Pb CF
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT
Top Premarket Gainers MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment DJ
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study MT
CAC40: below 7600 pts, held back by the automotive sector CF
Vigil Neuroscience Receives $40 Million Investment From Sanofi MT
The same old winners Our Logo
Sanofi: positive publication for Dupixent in NEJM CF
Sanofi Partakes in Formation Bio's $372 Million Fundraising MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.85 EUR
Average target price
107.9 EUR
Spread / Average Target
+17.43%
Consensus
1st Jan change Capi.
+2.33% 12TCr
+56.86% 82TCr
+43.90% 64TCr
-6.57% 35TCr
+17.32% 32TCr
+9.94% 30TCr
+16.08% 24TCr
+2.29% 22TCr
+13.96% 22TCr
+7.98% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Picks Second Therapeutic Target Under In Vivo Collaboration With Scribe Therapeutics